Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

S. Freeman · SciRah

Researcher profile · Semantic Scholar

S. Freeman

Share profile

S. Freeman — researcher profile on SciRah

h-index: 36
Works: 105
Citations: 7,282

Most-cited papers

Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party.
G. Schuurhuis, M. Heuser, S. Freeman, M. Béné +20 more
2018Blood957 citations Open access
Semantic Scholar
Assessment of Minimal Residual Disease in Standard-Risk AML.
A. Ivey, R. Hills, M. Simpson, J. Jovanovic +18 more
2016New England Journal of Medicine777 citations Open access
Semantic Scholar
2021 Update Measurable Residual Disease in Acute Myeloid Leukemia: European LeukemiaNet Working Party Consensus Document.
M. Heuser, S. Freeman, G. Ossenkoppele, F. Buccisano +41 more
2021Blood564 citations Open access
Semantic Scholar
Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia.
A. Burnett, N. Russell, R. Hills, J. Kell +8 more
2012Journal of Clinical Oncology403 citations
Semantic Scholar
Association of Measurable Residual Disease With Survival Outcomes in Patients With Acute Myeloid Leukemia: A Systematic Review and Meta-analysis.
N. Short, Shou-Hao Zhou, Chen-Qi Fu, D. Berry +9 more
2020JAMA Oncology366 citations Open access
Semantic Scholar
Prognostic relevance of treatment response measured by flow cytometric residual disease detection in older patients with acute myeloid leukemia.
S. Freeman, P. Virgo, S. Couzens, D. Grimwade +3 more
2013Journal of Clinical Oncology303 citations
Semantic Scholar
2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party
M. Heuser, S. Freeman, G. Ossenkoppele, F. Buccisano +38 more
2021272 citations
Semantic Scholar
Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for "prime time"?
D. Grimwade, S. Freeman
2014Blood269 citations Open access
Semantic Scholar
Acute myeloid leukaemia.
C. Dinardo, H. Erba, S. Freeman, A. Wei
2023The Lancet191 citations Open access
Semantic Scholar
Measurable Residual Disease at Induction Redefines Partial Response in Acute Myeloid Leukemia and Stratifies Outcomes in Patients at Standard Risk Without NPM1 Mutations.
S. Freeman, R. Hills, P. Virgo, Naeem Khan +13 more
2018Journal of Clinical Oncology185 citations Open access
Semantic Scholar
Unified classification and risk-stratification in Acute Myeloid Leukemia
Yanis Tazi, J. Arango-Ossa, Yang-Yu Zhou, E. Bernard +23 more
2022Nature Communications174 citations Open access
Semantic Scholar
Multicenter validation of a reproducible flow cytometric score for the diagnosis of low-grade myelodysplastic syndromes: results of a European LeukemiaNET study
M. D. della Porta, C. Picone, C. Pascutto, L. Malcovati +12 more
2012Haematologica165 citations Open access
Semantic Scholar
Molecular MRD status and outcome after transplantation in NPM1 mutated AML: results from the UK NCRI AML17 study.
Richard Dillon, R. Hills, S. Freeman, N. Potter +35 more
2019Blood156 citations Open access
Semantic Scholar
Evaluating measurable residual disease in acute myeloid leukemia.
F. Ravandi, R. Walter, S. Freeman
2018Blood Advances147 citations Open access
Semantic Scholar
Genetically distinct leukemic stem cells in human CD34− acute myeloid leukemia are arrested at a hemopoietic precursor-like stage
L. Quek, G. Otto, C. Garnett, L. Lhermitte +29 more
2016Journal of Experimental Medicine144 citations Open access
Semantic Scholar
Azacitidine fails to eradicate leukemic stem/progenitor cell populations in patients with acute myeloid leukemia and myelodysplasia
C. Craddock, L. Quek, N. Goardon, S. Freeman +21 more
2013Leukemia141 citations Open access
Semantic Scholar
Augmented Reduced-Intensity Regimen Does Not Improve Postallogeneic Transplant Outcomes in Acute Myeloid Leukemia
C. Craddock, Aimee Jackson, J. Loke, S. Siddique +23 more
2020Journal of Clinical Oncology128 citations Open access
Semantic Scholar
Contrasting requirements during disease evolution identify EZH2 as a therapeutic target in AML
Faisal Basheer, G. Giotopoulos, Eshwar Meduri, Hai-Yang Yun +20 more
2019Journal of Experimental Medicine106 citations Open access
Semantic Scholar
Molecular, clinical and therapeutic determinants of outcome in NPM1 mutated AML.
J. Othman, N. Potter, A. Ivey, Yanis Tazi +23 more
2024Blood98 citations Open access
Semantic Scholar
Technical Aspects of Flow Cytometry-based Measurable Residual Disease Quantification in Acute Myeloid Leukemia: Experience of the European LeukemiaNet MRD Working Party
J. Tettero, S. Freeman, Veit L. Buecklein, A. Venditti +21 more
2021HemaSphere91 citations Open access
Semantic Scholar
Assessment of minimal residual disease in acute myeloid leukemia
D. Grimwade, P. Vyas, S. Freeman
2010Current Opinion in Oncology82 citations
Semantic Scholar
Post induction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission.
J. Othman, N. Potter, A. Ivey, Jelena Jovanovic +16 more
2024Blood81 citations Open access
Semantic Scholar
Expression of CD33 is a predictive factor for effect of Gemtuzumab Ozogamicin at different doses in adult acute myeloid leukemia
Naeem Khan, R. Hills, P. Virgo, S. Couzens +8 more
2016Leukemia74 citations Open access
Semantic Scholar
Pretreatment haematological laboratory values predict for excessive myelosuppression in patients receiving adjuvant FEC chemotherapy for breast cancer.
P. Jenkins, S. Freeman
2009Annals of Oncology73 citations Open access
Semantic Scholar
A randomized comparison of CPX-351 and FLAG-Ida in adverse karyotype AML and high-risk MDS: the UK NCRI AML19 trial
J. Othman, C. Wilhelm-Benartzi, R. Dillon, S. Knapper +18 more
2023Blood Advances64 citations Open access
Semantic Scholar
Association of Hematologic Response and Assay Sensitivity on the Prognostic Impact of Measurable Residual Disease in Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis
N. Short, Chen-Qi Fu, D. Berry, R. Walter +9 more
2022Leukemia51 citations
Semantic Scholar
FLT3 inhibitors as MRD-guided salvage treatment for molecular failure in FLT3 mutated AML
J. Othman, N. Potter, K. Mokretar, D. Taussig +34 more
2023Leukemia46 citations Open access
Semantic Scholar
Posttransplant MRD and T-cell chimerism status predict outcomes in patients who received allografts for AML/MDS
J. Loke, Nicholas I. McCarthy, Aimee Jackson, S. Siddique +16 more
2023Blood Advances43 citations Open access
Semantic Scholar
How we use molecular minimal residual disease (MRD) testing in acute myeloid leukaemia (AML)
R. Dillon, N. Potter, S. Freeman, N. Russell
2020British Journal of Haematology43 citations Open access
Semantic Scholar
No evidence that CD33 splicing SNP impacts the response to GO in younger adults with AML treated on UK MRC/NCRI trials.
R. Gale, T. Popa, Melissa Wright, Naeem Khan +5 more
2018Blood42 citations Open access
Semantic Scholar
Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With NPM1 and FLT3 Mutations
Nigel H. Russell, Charlotte S Wilhelm-Benartzi, J. Othman, Richard Dillon +15 more
2024Journal of Clinical Oncology41 citations Open access
Semantic Scholar
Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for "prime time"?
D. Grimwade, S. Freeman
2014Hematology. American Society of Hematology. Education Program40 citations Open access
Semantic Scholar
Fractionated vs single-dose gemtuzumab ozogamicin with determinants of benefit in older patients with AML: the UK NCRI AML18 trial
S. Freeman, Abin Thomas, Ian Thomas, R. Hills +18 more
2023Blood39 citations Open access
Semantic Scholar
MRD evaluation of AML in clinical practice: are we there yet?
S. Freeman, C. Hourigan
2019Hematology. American Society of Hematology. Education Program37 citations Open access
Semantic Scholar
Validation of a predictive model that identifies patients at high risk of developing febrile neutropaenia following chemotherapy for breast cancer.
P. Jenkins, J. Scaife, S. Freeman
2012Annals of Oncology35 citations Open access
Semantic Scholar
Reproducible measurable residual disease detection by multiparametric flow cytometry in acute myeloid leukemia
M. Rohnert, M. Kramer, Jonas Schadt, P. Ensel +12 more
2022Leukemia30 citations Open access
Semantic Scholar
Reduced CD38 expression on CD34+ cells as a diagnostic test in myelodysplastic syndromes
N. Goardon, E. Nikolousis, A. Sternberg, Wai-Kit Chu +7 more
2009Haematologica30 citations Open access
Semantic Scholar
Prognostic value of monitoring a candidate immunophenotypic leukemic stem/progenitor cell population in patients allografted for acute myeloid leukemia
C. Bradbury, Aimee E. Houlton, Susanna Akiki, R. Gregg +13 more
2014Leukemia29 citations Open access
Semantic Scholar
Measurable Residual Disease Monitoring in Patients with Acute Myeloid Leukemia Treated with Lower Intensity Therapy: Roadmap from an ELN-DAVID Expert Panel
F. Ravandi, Jacqueline Cloos, F. Buccisano, R. Dillon +13 more
2023American journal of hematology/oncology28 citations Open access
Semantic Scholar
Defining the Optimal Total Number of Chemotherapy Courses in Younger Patients With Acute Myeloid Leukemia: A Comparison of Three Versus Four Courses
A. Burnett, N. Russell, R. Hills, S. Knapper +9 more
2020Journal of Clinical Oncology27 citations Open access
Semantic Scholar
Outcomes of older patients aged 60 to 70 years undergoing reduced intensity transplant for acute myeloblastic leukemia: results of the NCRI acute myeloid leukemia 16 trial
N. Russell, R. Hills, Abin Thomas, Ian Thomas +6 more
2021Haematologica26 citations Open access
Semantic Scholar
MYBL2 haploinsufficiency increases susceptibility to age-related haematopoietic neoplasia
Mary L. Clarke, S. Dumon, C. Ward, R. Jäger +7 more
2012Leukemia26 citations Open access
Semantic Scholar
Role of Minimal (Measurable) Residual Disease Assessment in Older Patients with Acute Myeloid Leukemia
F. Buccisano, R. Dillon, S. Freeman, A. Venditti
2018Cancers25 citations Open access
Semantic Scholar
Serum Flt3 ligand is a biomarker of progenitor cell mass and prognosis in acute myeloid leukemia.
P. Milne, C. Wilhelm-Benartzi, M. Grunwald, V. Bigley +14 more
2019Blood Advances24 citations Open access
Semantic Scholar
A comparison of FLAG-Ida and daunorubicin combined with clofarabine in high-risk acute myeloid leukaemia: data from the UK NCRI AML17 Trial
Alan Burnett, R. Hills, Ove Juul Nielsen, S. Freeman +5 more
2018Leukemia21 citations Open access
Semantic Scholar
Elevated FOSB‐expression; a potential marker of valproate sensitivity in AML
F. Khanim, C. Bradbury, Julie Arrazi, R. Hayden +13 more
2009British Journal of Haematology21 citations
Semantic Scholar
Pre-emptive detection and evolution of relapse in acute myeloid leukemia by flow cytometric measurable residual disease surveillance
Nicholas H. McCarthy, G. Gui, F. Dumézy, C. Roumier +9 more
2024Leukemia18 citations Open access
Semantic Scholar
Applicability and reproducibility of acute myeloid leukaemia stem cell assessment in a multi‐centre setting
Diana Hanekamp, Alexander N. Snel, A. Kelder, W. Scholten +21 more
2020British Journal of Haematology17 citations Open access
Semantic Scholar
De ﬁ ning minimal residual disease in acute myeloid leukemia: which platforms are ready for “ prime time ” ?
D. Grimwade, S. Freeman
201417 citations
Semantic Scholar
Standardising acute myeloid leukaemia classification systems: a perspective from a panel of international experts.
R. Shallis, Naval G. Daver, J. Altman, R. Komrokji +37 more
2023The Lancet Haematology16 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

N. Russell×16
Invite
N. Russell — researcher profile on SciRah
R. Dillon×15
Invite
R. Dillon — researcher profile on SciRah
D. Grimwade×14
Invite
D. Grimwade — researcher profile on SciRah
R. Hills×14
Invite
R. Hills — researcher profile on SciRah

×12

Invite

A. Burnett — researcher profile on SciRah

C. Craddock×10

Invite

C. Craddock — researcher profile on SciRah

Invite

P. Vyas — researcher profile on SciRah

Invite

C. Hourigan — researcher profile on SciRah

Invite

R. Walter — researcher profile on SciRah

Invite

Ian Thomas — researcher profile on SciRah

F. Buccisano×7

Invite

F. Buccisano — researcher profile on SciRah

Invite

A. Gilkes — researcher profile on SciRah